ViewRay Inc. (VRAYQ)
OTCMKTS: VRAYQ · Delayed Price · USD
0.00
0.00 (0.00%)
May 3, 2024, 4:00 PM EDT - Market closed
ViewRay Revenue
ViewRay had revenue of $105.86M in the twelve months ending March 31, 2023, with 44.09% growth year-over-year. Revenue in the quarter ending March 31, 2023 was $22.53M with 19.38% year-over-year growth. In the year 2022, ViewRay had annual revenue of $102.21M with 45.76% growth.
Revenue (ttm)
$105.86M
Revenue Growth
+44.09%
P/S Ratio
0.00
Revenue / Employee
$358,861
Employees
295
Market Cap
18.34K USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2022 | 102.21M | 32.09M | 45.76% |
Dec 31, 2021 | 70.12M | 13.10M | 22.98% |
Dec 31, 2020 | 57.02M | -30.77M | -35.05% |
Dec 31, 2019 | 87.78M | 6.82M | 8.42% |
Dec 31, 2018 | 80.96M | 46.92M | 137.83% |
Dec 31, 2017 | 34.04M | 11.81M | 53.09% |
Dec 31, 2016 | 22.24M | 11.85M | 114.02% |
Dec 31, 2015 | 10.39M | 3.99M | 62.37% |
Dec 31, 2014 | 6.40M | 3.24M | 102.56% |
Dec 31, 2013 | 3.16M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 371.62B |
Johnson & Johnson | 81.80B |
Merck & Co. | 60.12B |
AbbVie | 54.40B |
Novartis AG | 49.92B |
AstraZeneca | 47.61B |
Thermo Fisher | 42.49B |
Abbott Laboratories | 40.33B |
VRAYQ News
- 7 months ago - Open Letter to ViewRay Customers, Service, Software Engineers and Suppliers—Let's Preserve ViewRay Technology - Business Wire
- 7 months ago - Letter to ViewRay Lenders/Investment Bankers and Customers From Krishnan Suthanthiran, President/Founder of TeamBest Global Companies - Business Wire
- 7 months ago - Open Letter to ViewRay Customers From Krishnan Suthanthiran, President/Founder of TeamBest Global Companies - Business Wire
- 10 months ago - ViewRay® Announces Commencement of Nasdaq Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Markets - PRNewsWire
- 10 months ago - ViewRay® Files Voluntary Chapter 11 Petitions - PRNewsWire
- 11 months ago - VA Oklahoma City Healthcare System Chooses ViewRay's MRIdian® MRI-Guided Radiation Therapy System - PRNewsWire
- 1 year ago - Top 5 Health Care Stocks That Could Blast Off In May - Coherus BioSciences (NASDAQ:CHRS), Intercept Pharma (NASDAQ:ICPT) - Benzinga
- 1 year ago - ViewRay's MRIdian® to be Featured at Leading European Radiation Oncology Meeting - PRNewsWire